Navigation Links
Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
Date:5/2/2011

could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties relating to the proposed merger, as detailed from time to time in Valeant's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Investors:
Laurie W. Little    
Valeant Pharmaceuticals International, Inc.  
949-461-6002    
laurie.little@valeant.com      

Media:
Renee E. Soto
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com

Cassandra Bujarski
Sard Verbinnen & Co.

212-687-8080
cbujarski@sardverb.com

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
2. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
3. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
4. Regulatory Update - GSK and Valeant Respond to FDA on ezogabine
5. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
6. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
7. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
8. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
9. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
10. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
11. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today announced ... version of vigabatrin) for the treatment of cocaine and ... based upon, an in-depth review of the results obtained ... use of CPP-109 for the treatment of cocaine addiction ...
... Blue Belt Technologies, Inc., a Pittsburgh based medical device ... for use in orthopaedic and neurosurgery procedures, has closed ... of financing. The round was led by private ... Innovation Works (Pittsburgh) and consisted of both new investments ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 4Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 5Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 6Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... a,new online resource for OTC drugs that have no negative side ... to know that non-toxic drugs are available today as,options to successfully ... are able to achieve relief without the adverse side effects,such as ... so many of us. , ...
... Stephen Joffe, Craig Joffe, and,Alan Buckey today filed an ... Exchange Commission. The group previously filed a 13D,disclosing ... LCAV ), which,operates 77 LasikPlus fixed-site laser vision correction ... Joffe is the founder and former Chairman and CEO ...
... did limit vomiting and results are preliminary, researchers ... Children who were given the steroid dexamethasone after ... they also faced an increased risk of bleeding ... early for safety reasons, a new study shows. ...
... inoperable disease, report says , , TUESDAY, Dec. 9 (HealthDay ... have improved overall survival of patients with advanced breast ... review of 128 clinical trials that included more than ... that use of anthracycline regimens led to a 22 ...
... deadliness of Alzheimer,s, report says , , TUESDAY, Dec. 9 ... fail to record severe dementia as a cause of death ... only points to a lack of knowledge about how dementia ... deadly illness, it suggests that deaths due to Alzheimer,s and ...
... for the Prom a Winner, Features Kelli Pedroia , ... Academy of Dermatology has announced that the Melanoma Foundation of New ... given for "significant contributions to the specialty of dermatology." The award ... in March of 2009. , , ...
Cached Medicine News:Health News:New Resource for No Side Effect Drugs 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 3Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 4Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 5Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 6Health News:Steroid After Tonsillectomy Raises Bleeding Risk 2Health News:Steroid After Tonsillectomy Raises Bleeding Risk 3Health News:Non-Hormonal Therapies Aid Breast Cancer Patients 2Health News:Dementia Often Missed as Cause of Death 2Health News:Dementia Often Missed as Cause of Death 3Health News:Melanoma Foundation of New England Wins Gold Triangle Award From the American Academy of Dermatology 2
Shandon Excelsior ES Tissue Processor continues the Thermo Electron Corporation tradition of offering one of the most advanced, traditional reagent instruments available today....
... the highly concentrated multi-purpose detergent formulated ... with an ultrasonic cleaner. MPD ... and organic material and safe enough ... clean surgical instruments manually or with ...
... grip the patients finger snugly. Wrap the patients ... Steel Finger Trap for an extra secure fit ... create a complete upper extremity traction system when ... Advanced Universal K Table. Stainless Steel Finger Traps ...
... Transmitters slot into ... TeleMon companion monitor, so ... at the patient's side. ... interrupting transmission and storage ...
Medicine Products: